Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Sanderling Ventures is a prominent venture capital firm founded in 1979 and headquartered in the United States. With over four decades of experience, the firm has established itself as a leader in the early-stage financing of biomedical companies. Sanderling Ventures has successfully supported more than 90 companies in the biomedical sector, emphasizing close partnerships with entrepreneurs to drive significant growth and innovation. The firm is known for its active management approach, which includes providing not only capital but also strategic guidance and operational support to its portfolio companies.
Throughout its history, Sanderling Ventures has built a reputation for fostering the development of groundbreaking technologies in the healthcare and biotech industries. The firm’s leadership team comprises seasoned professionals with extensive backgrounds in biomedical research, entrepreneurship, and venture capital, enabling them to offer valuable insights and resources to their portfolio companies. Sanderling Ventures has raised multiple funds over the years, focusing on early-stage investments that align with its mission to build new biomedical companies.
Sanderling Ventures specializes in investing in early-stage biomedical companies, with a strong emphasis on sectors such as small molecule therapeutics, biologics and vaccines, drug delivery systems, platform technologies, and medical devices. The firm seeks to identify innovative startups that are poised to make significant impacts in the healthcare landscape. Sanderling Ventures provides seed and early-stage funding, which is critical for startups looking to develop their technologies and bring them to market.
In addition to financial support, Sanderling Ventures is committed to active management and long-term partnerships with its portfolio companies. This includes offering management leadership, technical expertise, and regulatory guidance to help navigate the complexities of the biomedical industry. The firm also implements cost-control strategies to ensure that its companies can operate efficiently and effectively as they scale. By focusing on these key areas, Sanderling Ventures aims to foster substantial growth and innovation within the biomedical sector.
Sanderling Ventures boasts a diverse portfolio of over 90 companies, many of which have achieved notable success in the biomedical field. Among its most distinguished investments are **Actimis**, which was acquired by Boehringer Ingelheim; **Aderis**, acquired by Schwarz Pharma; and **Advanced Cardiovascular**, which was acquired by Guidant Corp. (now part of Boston Scientific). Other significant portfolio companies include **Altor BioScience**, acquired by ImmunityBio, Inc.; **CalciMedica**, which is listed on NASDAQ under the ticker CALC; **Chimerix**, listed on NASDAQ as CMRX; **Dendreon**, listed on NASDAQ as DNDN; **Dynavax**, listed on NASDAQ as DVAX; and **Regeneron**, listed on NASDAQ as REGN.
These successful exits and public listings highlight Sanderling Ventures' ability to identify and nurture promising biomedical companies. The firm’s portfolio reflects its commitment to supporting innovative solutions in healthcare, and its track record of successful investments positions it as a key player in the venture capital landscape.
Sanderling Ventures primarily invests in the angel, pre-seed, and seed stages of biomedical companies. This focus allows them to support startups at critical points in their development, providing the necessary capital and resources to help them grow.
Founders interested in pitching Sanderling Ventures should prepare a comprehensive presentation that outlines their business model, market opportunity, and technology. While specific submission guidelines are not provided, a well-structured pitch that clearly articulates the value proposition is essential.
Sanderling Ventures focuses on the biomedical sector, investing in areas such as small molecule therapeutics, biologics and vaccines, drug delivery, platform technologies, and medical devices. This specialization allows them to leverage their expertise in these fields.
While specific check sizes are not disclosed, Sanderling Ventures provides seed and early-stage funding, which typically ranges from hundreds of thousands to several million dollars, depending on the needs of the startup.
Sanderling Ventures primarily invests in companies based in the United States. Their focus on the US market allows them to engage closely with entrepreneurs and the biomedical ecosystem.
Sanderling Ventures offers extensive support to its portfolio companies, including management leadership, technical and regulatory expertise, and cost-control strategies. This active management approach is designed to foster significant growth and innovation.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.